Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ALDX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | A Clinical Trial in Subjects With Atopic Dermatitis (Part 1) NCT05717920 · Atopic Dermatitis ADX-629 (Open-label) | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 8 | Nov 21, 2023 | Registry ↗ |
| Jun 3, 2026 | A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatiti… NCT06685692 · Alcohol Hepatitis ADX-629, ADX-629 | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 4 | Jun 18, 2025 | Registry ↗ |
| May 14, 2026 | The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasona… NCT05234554 · Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic… | ALDX Aldeyra Therapeutics, Inc. | Phase 3 | Completed | 131 | Apr 22, 2023 | Registry ↗ |
| Apr 23, 2026 | A Study in Subjects With Retinitis Pigmentosa NCT05392179 · Retinitis Pigmentosa ADX-2191, ADX-2191 | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 8 | Jun 23, 2023 | Registry ↗ |
| Feb 11, 2026 | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma NCT07402876 · Primary Vitreoretinal Lymphoma ICM ADX-2191 injection, Monthly ADX-2191 injection | ALDX Aldeyra Therapeutics, Inc. | Phase 3 | Recruiting | 20 | Dec 2026 | Registry ↗ |
| Dec 22, 2025 | A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease NCT06493604 · Dry Eye Disease Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic… | ALDX Aldeyra Therapeutics, Inc. | Phase 3 | Completed | 116 | Feb 27, 2025 | Registry ↗ |
| Nov 26, 2025 | A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evalua… NCT04735393 · Dry Eye Disease Reproxalap Ophthalmic Solution (0.25%), Placebo Comparator | ALDX Aldeyra Therapeutics, Inc. | Phase 3 | Completed | 757 | Oct 11, 2022 | Registry ↗ |
| Oct 1, 2025 | A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease NCT06424444 · Dry Eye Disease Reproxalap ophthalmic solution (0.25%), Vehicle ophthalmic… | ALDX Aldeyra Therapeutics, Inc. | Phase 3 | Completed | 421 | Nov 3, 2024 | Registry ↗ |
| Jul 9, 2025 | The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy NCT04136366 · Proliferative Vitreoretinopathy ADX-2191 (intravitreal methotrexate 0.8%), Standard surgica… | ALDX Aldeyra Therapeutics, Inc. | Phase 3 | Completed | 106 | Jun 14, 2022 | Registry ↗ |
| Jun 5, 2025 | A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease NCT06389214 · Dry Eye Disease Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic… | ALDX Aldeyra Therapeutics, Inc. | Phase 3 | Completed | 132 | Jun 11, 2024 | Registry ↗ |
| Apr 8, 2025 | A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Alle… NCT03660878 · Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalm… | ALDX Aldeyra Therapeutics, Inc. | Phase 1/2 | Completed | 52 | Nov 19, 2019 | Registry ↗ |
| Mar 19, 2025 | The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Di… NCT04674358 · Dry Eye, Dry Eye Syndromes Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic S… | ALDX Aldeyra Therapeutics, Inc. | Phase 2/3 | Completed | 329 | Sep 12, 2021 | Registry ↗ |
| Mar 18, 2025 | The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects Wit… NCT05062330 · Dry Eye Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic… | ALDX Aldeyra Therapeutics, Inc. | Phase 3 | Completed | 361 | Mar 4, 2022 | Registry ↗ |
| Mar 11, 2025 | A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psorias… NCT04908514 · Plaque Psoriasis ADX-629 | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 10 | Jan 21, 2022 | Registry ↗ |
| Mar 3, 2025 | A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Re… NCT03916042 · Dry Eye Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QI… | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 206 | Nov 22, 2019 | Registry ↗ |
| Feb 28, 2025 | A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethano… NCT05487404 · Ethanol Intoxication ADX-629, Placebo | ALDX Aldeyra Therapeutics, Inc. | Phase 1/2 | Completed | 26 | May 29, 2022 | Registry ↗ |
| Feb 28, 2025 | A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough NCT05392192 · Chronic Cough ADX-629, Placebo | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 51 | Apr 13, 2023 | Registry ↗ |
| Feb 28, 2025 | An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a… NCT05102409 · Dry Eye Reproxalap Ophthalmic Solution (0.25%), Xiidra® (5% lifiteg… | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 56 | Oct 25, 2021 | Registry ↗ |
| Feb 24, 2025 | A Clinical Trial to Assess Subjects With Dry Eye Disease. NCT04971031 · Dry Eye Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic… | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 158 | Sep 8, 2021 | Registry ↗ |
| Feb 24, 2025 | A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjuncti… NCT03709121 · Conjunctivitis, Allergic Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalm… | ALDX Aldeyra Therapeutics, Inc. | Phase 1/2 | Completed | 70 | Mar 20, 2019 | Registry ↗ |
| Feb 17, 2025 | A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability… NCT04847544 · Covid19 ADX-629, Placebo | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 11 | Oct 15, 2021 | Registry ↗ |
| Feb 17, 2025 | A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety… NCT04728711 · Atopic Asthma ADX-629, Placebo | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 8 | Jan 18, 2022 | Registry ↗ |
| Feb 11, 2025 | ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis NCT03494504 · Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalm… | ALDX Aldeyra Therapeutics, Inc. | Phase 3 | Completed | 318 | Nov 5, 2018 | Registry ↗ |
| Feb 10, 2025 | SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis. NCT03131154 · Non-infectious Anterior Uveitis ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Opht… | ALDX Aldeyra Therapeutics, Inc. | Phase 3 | Completed | 123 | Apr 19, 2019 | Registry ↗ |
| Feb 6, 2025 | A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to As… NCT03404115 · Dry Eye Syndrome Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalm… | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 300 | Jul 11, 2018 | Registry ↗ |
| Jan 23, 2025 | The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Ada… NCT03879863 · Dry Eye Reproxalap Ophthalmic Solution (0.25%) QID, Vehicle Ophthal… | ALDX Aldeyra Therapeutics, Inc. | Phase 3 | Completed | 422 | Oct 4, 2019 | Registry ↗ |
| Jan 16, 2025 | A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome NCT03162783 · Dry Eye Syndromes ADX-102 Ophthalmic Solution (0.5%), ADX-102 Ophthalmic Solu… | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 51 | Jul 6, 2017 | Registry ↗ |
| Jan 15, 2025 | A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease NCT05424549 · Dry Eye Syndromes Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic… | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 63 | May 9, 2022 | Registry ↗ |
| Nov 20, 2024 | The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal… NCT04207736 · Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic… | ALDX Aldeyra Therapeutics, Inc. | Phase 3 | Completed | 95 | Feb 16, 2021 | Registry ↗ |
| Apr 17, 2024 | Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syn… NCT05599815 · Nephrotic Syndrome ADX-629 | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Withdrawn | 0 | May 2023 | Registry ↗ |
| Dec 5, 2023 | A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis NCT02578914 · Allergic Conjunctivitis, Seasonal Allergies NS2 Ophthalmic Drops (0.5%), NS2 Ophthalmic Drops Vehicle (… | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 100 | Dec 2015 | Registry ↗ |
| Mar 27, 2023 | A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis NCT02406209 · Non-infectious Anterior Uveitis NS2, Prednisolone acetate ophthalmic suspension (1%) | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 45 | Apr 2016 | Registry ↗ |
| Feb 9, 2023 | RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS) NCT03445650 · Sjogren-Larsson Syndrome ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of AD… | ALDX Aldeyra Therapeutics, Inc. | Phase 3 | Completed | 11 | Jan 18, 2020 | Registry ↗ |
| Jan 9, 2023 | A Study of ADX-102 in Subjects With Allergic Conjunctivitis NCT03012165 · Conjunctivitis, Allergic ADX-102 Ophthalmic Drops (0.5%), ADX-102 Ophthalmic Drops (… | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 154 | May 2017 | Registry ↗ |
| Dec 13, 2022 | A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS) NCT02402309 · Sjögren-Larsson Syndrome Active topical NS2 1% dermatologic cream, Vehicle placebo 0… | ALDX Aldeyra Therapeutics, Inc. | Phase 2 | Completed | 12 | May 2016 | Registry ↗ |
35 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:44 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances